Elevated SARS-CoV-2 in peripheral blood and increased COVID-19 severity in American Indians/Alaska Natives

作者：Douglas J. Perkins, Alexandra Yingling, Qiuying Cheng, Amber Castillo, Janae Martinez, Steven B. Bradfute, Shuguang Leng, Jeremy S. Edwards, Yan Guo, Grégory Mertz, Michelle Harkins, Mark Aaron Unruh, Anthony Worsham, Christophe G Lambert, J. Pedro Teixeira, Phillip Seidenberg, Jens Langsjoen, Kristan A. Schneider, Ivy Hurwitz · 发表于：Experimental Biology and Medicine · 年份：2022 · DOI：10.1177/15353702221091180 · 被引用次数：9 · 研究领域：COVID-19 Clinical Research Studies、SARS-CoV-2 and COVID-19 Research、SARS-CoV-2 detection and testing

Epidemiological data across the United States show health disparities in COVID-19 infection, hospitalization, and mortality by race/ethnicity. While the association between elevated SARS-CoV-2 viral loads (VLs) (i.e. upper respiratory tract (URT) and peripheral blood (PB)) and increased COVID-19 severity has been reported, data remain largely unavailable for some disproportionately impacted racial/ethnic groups, particularly for American Indian or Alaska Native (AI/AN) populations. As such, we determined the relationship between SARS-CoV-2 VL dynamics and disease severity in a diverse cohort of hospitalized patients. Results presented here are for study participants ( n = 94, ages 21–88 years) enrolled in a prospective observational study between May and October 2020 who had SARS-CoV-2 viral clades 20A, C, and G. Based on self-reported race/ethnicity and sample size distribution, the cohort was stratified into two groups: (AI/AN, n = 43) and all other races/ethnicities combined (non-AI/AN, n = 51). SARS-CoV-2 VLs were quantified in the URT and PB on days 0–3, 6, 9, and 14. The strongest predictor of severe COVID-19 in the study population was the mean VL in PB (OR = 3.34; P = 2.00 × 10 −4 ). The AI/AN group had the following: (1) comparable co-morbidities and admission laboratory values, yet more severe COVID-19 (OR = 4.81; P = 0.014); (2) a 2.1 longer duration of hospital stay ( P = 0.023); and (3) higher initial and cumulative PB VLs during severe disease ( P = 0.025). More...